Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.03) by 4....
-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study ---- To date, no delayed neurotox...
Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $121 to $130.
Stifel analyst Stephen Willey reinstates Arcellx (NASDAQ:ACLX) with a Buy and announces $129 price target.
Cantor Fitzgerald analyst Eric Schmidt assumes Arcellx (NASDAQ:ACLX) with a Neutral rating and announces Price Target of $88.
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.05) by 10...
Scotiabank analyst George Farmer maintains Arcellx (NASDAQ:ACLX) with a Sector Outperform and raises the price target from $...
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and a...
